Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice (1983)
    Springer
    Cancer chemotherapy and pharmacology 10 (1983), S. 182-186 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary To validate the usefulness of a human tumor-nude mice xenograft system as a potential model in the secondary screening of anticancer agents, the antitumor activity of 17 anticancer drugs has been studied in the treatment of a human breast cancer tumor (MX-1) transplanted to nude mice. For evaluation of the antitumor activity of the drugs we employed the LD10 predetermined in BDF1 mice as a standard therapeutic dose. Drugs were administered IV, IP, or PO, and antitumor activity was assessed by drug-induced growth inhibition measured by caliper. Among the 17 anticancer drugs, the most active compounds (maximum inhibition rate of tumor growth: ≥90%) are mitomycin C, chromomycin A3, vincristine, vinblastine, vindesine, and hexamethylmelamine. Another group of compounds showed moderate activity (maximum inhibition rate of tumor growth: 89%–50%), these being adriamycin, daunomycin, mitoxantrone, bleomycin, 5-FU, 6-TG, and ftorafur. The remaining four drugs (peplomycin, cytosine arabinoside, 6-MP, and methotrexate) were inactive against the MX-1 tumor. These results suggested that in the nude mouse-human tumor xenograft system of the MX-1 tumor there was a good correlation between the antitumor activity of various anticancer drugs and their clinical efficacy; this system is therefore expected to be a useful model for the secondary screening system.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00255758
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Clinical and immunological studies of human fibroblast interferon (1982)
    Springer
    Cancer chemotherapy and pharmacology 8 (1982), S. 47-55 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Human fibroblast interferon (HFIF) was used in 26 patients with various malignant diseases, most of whom had received previous chemotherapy. The dosages used were 3x106IU or 6x106IU HFIF IV daily. Of 24 evaluable patients, two attained partial remissions (one with chronic lymphocytic leukemia and one with multiple myeloma), and seven (stomach Ca two, multiple myeloma two, CLL one, malignant melanoma one, and non-Hodgkin's lymphoma one) attained stable disease. The majority of patients experienced fever with body temperature exceeding 38° C and chills, which became uncommon after several days of treatment. Other side-effects included myelosuppression, general malaise, anorexia, hepatic dysfunction, and renal dysfunction, which were mild and tolerable. Lymphocyte natural killer (NK) activity against culture cell lines was measured before and at various times after HFIF treatment. The majority of patients reached the highest NK activity at 18–24 h, mostly at 24 h after the initiation of HFIF therapy. In one group of patients NK activity subsequently remained at the highest level during HFIF treatment, while in another group of patients NK activity declined even with daily infusion of HFIF but usually remained above the pretreatment level. There seemed to be no correlation between NK activity and clinical activity. In contrast to NK activity against culture cell lines, no increase in lymphocyte cytotoxic activity against autologous tumor cells was observed following HFIF treatment. Mixed lymphocyte tumor cell reactions were tested in six patients and showed a slight increase of 3H-thymidine uptake in one patient, but the others had no change. In vitro sensitization to assess the in vitro generation of cytotoxic cells was negative in all six patients. Lymphocyte blastogenic responses to nonspecific mitogens showed no significant change. The delayed-type hypersensitivity reaction to recall antigens was increased in about half the patients after HFIF treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00292871
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer (1984)
    Springer
    Cancer chemotherapy and pharmacology 13 (1984), S. 95-99 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A prospective randomized trial was conducted comparing the clinical response of 60 patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide, and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM). The response rate was 12 of 28 (43%) in ACF and 18 of 30 (60%) in ACFM. Responses were seen more frequently in patients in whom fewer than two organs were involved, and responses at dominant metastatic sites were equal for the two arms. The response duration was 21+ (3.5–49.5+) months with ACF, as against 6.9 (1.9–30.8+) months with ACFM (P〈0.05). The median survival time from start of therapy was 20.8+ months for ACF, while that for ACFM was 13+ months (statistically not significant). The major toxicities were hair loss, GI toxicity, and leukopenia. The response rate with ACFM was higher than that with ACF, but the addition of methotrexate to ACF did not increase the complete response rate or prolong response duration.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00257122
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Phase I clinical trial of a new anthracycline: 4′-o-tetrahydropyranyl adriamycin (1983)
    Springer
    Investigational new drugs 1 (1983), S. 169-172 
    Details
    ISSN: 1573-0646
    Keywords: anthracycline ; 4′-o-tetrahydropyranyl adriamycin ; phase I study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The phase I study of a new anthracycline, 4′-o-tetrahydropyranyl adriamycin, was performed. A dose limiting factor was leukopenia while thrombocytopenia was less frequent and a maximum tolerated dose was determined as 54 mg/m2. Mild gastrointestinal toxicities including anorexia, nausea and vomiting occurred in about half of the patients, while very minimal alopecia was seen in only one patient. A recommended dose for phase II study was established: 40 mg/m2 at 3-week intervals.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00172076
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Activity of 4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system (1983)
    Springer
    Investigational new drugs 1 (1983), S. 271-275 
    Details
    ISSN: 1573-0646
    Keywords: THP-adriamycin ; in vitro activity ; human tumor cloning system ; ovarian cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary 4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) is a new anthracycline derivative. The antitumor activity of THP-ADM was tested on 51 human tumor samples representing ten different tumor types in in vitro colony assay method. Tested tumors were: 26 cases of ovarian cancer, 8 cases of breast cancer, 6 cases of colorectal cancer, 3 cases of endometrial cancer, 2 cases each with gastric cancer and sarcoma, and another 4 cases. An in vitro colony assay was done in soft agar as described by Hamburger & Salmon. The criteria for in vitro sensitivity was defined as a 70 percent or greater reduction in the number of colonies after a 1-h exposure to drugs. The selected concentrations of THP-ADM for assay were 0.05, 0.5, and 1.0 μg/ml. The sensitivity rates for THP-ADM in each dose were: 0.05 μg/ml (7/19, 37%), 0.5 μg/ml (10/51, 20%), and 1.0 μg/ml (12/19, 63%). In vitro sensitivity of adriamycin (0.04 μg/ml) was simultaneously tested in 49 cancer patients. Five out of 25 ovarian cancer patients (20%) showed responses to adriamycin and an overall response rate was 12% (6/49). These data indicate that THP-ADM has an antitumor activity against various cancers and it is comparable to that of adriamycin.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00177409
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C (1984)
    Springer
    Investigational new drugs 2 (1984), S. 381-385 
    Details
    ISSN: 1573-0646
    Keywords: Mitomycin C ; KW 2083 ; M 83 ; Phase I study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The Phase I study of N-7-(p-hydroxyphenyl)-mitomycin C (KW 2083, M 83) was performed. The dose-limiting toxicity was leukopenia and thrombocytopenia and a maximum tolerable dose was 70 mg/m2. Nonhematologic toxicities included nausea (44%), vomiting (13%), diarrhea (2.7%), azotemia (8.1%), proteinuria (5.4%), alopecia (8.1%) and elevated hepatic enzymes (2.7%). This Phase I study indicates that the recommended starting dose for Phase II studies for patients without significant myelosuppression would be 50 mg/m2 at 6 week intervals in an intravenous push. KW 2083 should be avoided in patients with impaired renal functions and proteinuria because of permanent renal damages caused by the drug.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00171589
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...